Linda S Elting1, Catherine D Cooksley, Mark S Chambers, Adam S Garden. 1. Section of Health Services Research, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. lelting@mdanderson.org
Abstract
PURPOSE: To study the risk, outcomes, and costs of radiation-induced oral mucositis (OM) among patients receiving radiotherapy (RT) to head and neck primary cancers. METHODS AND MATERIALS: A retrospective cohort consisting of 204 consecutive head-and-neck cancer patients who received RT with or without chemotherapy during 2002 was formed; their records were reviewed for clinical and resource use information. Patients who had received prior therapy, had second primary cancers, or received palliative radiation therapy were excluded. The risk of OM was analyzed by multiple variable logistic regression. The cost of care was computed from the provider's perspective in 2006 U.S. dollars and compared among patients with and without OM. RESULTS: Oral mucositis occurred in 91% of patients; in 66% it was severe (Grade 3-4). Oral mucositis was more common among patients with oral cavity or oropharynx primaries (odds ratio [OR], 44.5; 95% confidence interval [CI], 5.2 to >100; p < 0.001), those who received chemotherapy (OR = 7.8; 95% CI, 1.5-41.6; p = 0.02), and those who were treated with altered fractionation schedules (OR = 6.3; 95% CI, 1.1-35.1; p = 0.03). Patients with OM were significantly more likely to have severe pain (54% vs. 6%; p < 0.001) and a weight loss of > or =5% (60% vs. 17%; p < 0.001). Oral mucositis was associated with an incremental cost of $1700-$6000, depending on the grade. CONCLUSIONS: Head-and-neck RT causes OM in virtually all patients. Oral mucositis is associated with severe pain, significant weight loss, increased resource use, and excess cost. Preventive strategies are needed.
PURPOSE: To study the risk, outcomes, and costs of radiation-induced oral mucositis (OM) among patients receiving radiotherapy (RT) to head and neck primary cancers. METHODS AND MATERIALS: A retrospective cohort consisting of 204 consecutive head-and-neck cancerpatients who received RT with or without chemotherapy during 2002 was formed; their records were reviewed for clinical and resource use information. Patients who had received prior therapy, had second primary cancers, or received palliative radiation therapy were excluded. The risk of OM was analyzed by multiple variable logistic regression. The cost of care was computed from the provider's perspective in 2006 U.S. dollars and compared among patients with and without OM. RESULTS:Oral mucositis occurred in 91% of patients; in 66% it was severe (Grade 3-4). Oral mucositis was more common among patients with oral cavity or oropharynx primaries (odds ratio [OR], 44.5; 95% confidence interval [CI], 5.2 to >100; p < 0.001), those who received chemotherapy (OR = 7.8; 95% CI, 1.5-41.6; p = 0.02), and those who were treated with altered fractionation schedules (OR = 6.3; 95% CI, 1.1-35.1; p = 0.03). Patients with OM were significantly more likely to have severe pain (54% vs. 6%; p < 0.001) and a weight loss of > or =5% (60% vs. 17%; p < 0.001). Oral mucositis was associated with an incremental cost of $1700-$6000, depending on the grade. CONCLUSIONS: Head-and-neck RT causes OM in virtually all patients. Oral mucositis is associated with severe pain, significant weight loss, increased resource use, and excess cost. Preventive strategies are needed.
Authors: Rajesh V Lalla; Linda E Choquette; Kathleen F Curley; Robert J Dowsett; Richard S Feinn; Upendra P Hegde; Carol C Pilbeam; Andrew L Salner; Stephen T Sonis; Douglas E Peterson Journal: Oral Oncol Date: 2014-08-21 Impact factor: 5.337
Authors: Kranti A Mapuskar; Carryn M Anderson; Douglas R Spitz; Ines Batinic-Haberle; Bryan G Allen; Rebecca E Oberley-Deegan Journal: Semin Radiat Oncol Date: 2019-01 Impact factor: 5.934
Authors: Paolo Bossi; Gianmauro Numico; Vitaliana De Santis; Maria Grazia Ruo Redda; Alessia Reali; Liliana Belgioia; Maria Cossu Rocca; Ester Orlandi; Mario Airoldi; Alamalina Bacigalupo; Marta Mazzer; Gabriella Saibene; Elvio Russi Journal: Support Care Cancer Date: 2014-02-25 Impact factor: 3.603
Authors: Samuel R Birer; Chen-Ting Lee; Kingshuk Roy Choudhury; Kenneth H Young; Ivan Spasojevic; Ines Batinic-Haberle; James D Crapo; Mark W Dewhirst; Kathleen A Ashcraft Journal: Radiat Res Date: 2017-05-18 Impact factor: 2.841
Authors: Mohamed Zaid; Eugene J Koay; Nimit Bajaj; Ryan Mathew; Lianchun Xiao; Anshuman Agrawal; Pearl Fernandes; Hannah Burrows; Millicent A Roach; Christopher T Wilke; Caroline Chung; Clifton D Fuller; Jack Phan; G Brandon Gunn; William H Morrison; Adam S Garden; Steven J Frank; David I Rosenthal; Michael Andersen; Adegbenga Otun; Mark S Chambers Journal: Oral Oncol Date: 2020-04-13 Impact factor: 5.337